Ensign Peak Advisors
ABVX

Ensign Peak Advisors’s Abivax ABVX Stock Holding History

Ensign Peak Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.2M Sell
504,471
-127,367
-20% -$14.4M 0.11% 165
2026
Q1 		$70.4M Buy
631,838
+113,491
+22% +$13.4M 0.13% 151
2025
Q4 		$69.9M Buy
518,347
+62,663
+14% +$6.84M 0.12% 150
2025
Q3 		$38.7M Hold
455,684
– – 0.06% 230
2025
Q2 		$3.49M Hold
455,684
– – 0.01% 725
2025
Q1 		$2.85M Buy
+455,684
New +$3.08M 0.01% 782

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's ABVX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Abivax (ABVX) stake by 20% in Q2 2026, selling an estimated $14.4M and leaving 504,471 shares worth $67.2M. The position accounts for 0.11% of the portfolio, ranked #165.

Ensign Peak Advisors first reported a position in ABVX in Q1 2025 and has held it in 6 quarters since. The position peaked at $70.4M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Ensign Peak Advisors held 504,471 shares of Abivax worth $67.2M as of Q2 2026.
  • Ensign Peak Advisors sold 127,367 Abivax shares in Q2 2026, an estimated $14.4M.
  • Abivax made up 0.11% of Ensign Peak Advisors's portfolio in Q2 2026, its #165 holding.
  • Ensign Peak Advisors first reported a position in Abivax in Q1 2025 and has held it in 6 quarters since.
  • Ensign Peak Advisors's Abivax position peaked at $70.4M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.